



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

HR-NBL2/SIOPEN

The Gustave Roussy institute in France is responsible for the international implementation of the study (sponsor). The Swiss Paediatric Oncology Group (SPOG) is responsible for performing the study in Switzerland (sponsor's representative).

Background

Neuroblastoma is a rare cancer that manifests as lumps or tumours in the abdomen or in the vicinity of the spinal cord. If the cancer spreads throughout the body or has certain biological properties, it may become difficult to treat in children and adolescents. The specialists refer to such cases as high-risk neuroblastoma. In Switzerland about 5-6 patients a year are victims of this disease.

Why does the study need to be done?

The current standard treatment consists of various phases. The aim of this study is to define the best therapeutic strategy for improving the chances of cure in children and adolescents with high-risk neuroblastoma. For this purpose, the study compares two treatments in each of the various phases to find out which is the most effective and is best tolerated.

Contact details for the sponsor's representative in Switzerland:

SPOG Coordinating Center

Partner Relations

Effingerstrasse 33

3008 Bern

E-mail: partnerrelations@spog.ch

Phone: +41 31 389 91 89